Drug intelligence / Profile preview

SV-301

Development stage: Preclinical
Lead developer: Kangweizhonghe
Modality: Recombinant Proteins and Enzymes

Overview

SV-301 is an investigational drug candidate currently in the preclinical stage of development by Kangweizhonghe Biopharmaceutical. It is being developed for the treatment of uterine cervical cancer. As of the current pipeline disclosures, specific details regarding its molecular target, mechanism of action, and modality have not been publicly released. The drug is part of a broader oncology and infectious disease pipeline from Kangweizhonghe, which includes other candidates targeting HER2 and CD20.

Beyond the preview

Go deeper on SV-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SV-301.

Explore the full profile